08:47 EDT Vaxcyte (PCVX) sinks 35% to $45 after pneumococcal disease vaccine results
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study
- Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now
- Biotech Alert: Searches spiking for these stocks today
- Vaxcyte’s Earnings Call Highlights Strong Position and Future Growth
- Vaxcyte’s Promising Prospects and Strategic Engagements Justify Buy Rating